SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-027654
Filing Date
2022-11-02
Accepted
2022-11-02 06:45:52
Documents
16
Period of Report
2022-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20221102.htm   iXBRL 8-K 38669
2 EX-99.1 pressrelease-3q22financial.htm EX-99.1 82672
3 EX-99.2 pressrelease-adcdataxfinal.htm EX-99.2 53439
7 g1_logox2022xreg2.jpg GRAPHIC 75636
8 g1_logox2022xreg2a.jpg GRAPHIC 75636
  Complete submission text file 0001628280-22-027654.txt   542668

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20221102.xsd EX-101.SCH 1920
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20221102_lab.xml EX-101.LAB 24849
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20221102_pre.xml EX-101.PRE 13058
10 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20221102_htm.xml XML 11854
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 221352227
SIC: 2834 Pharmaceutical Preparations